Introduction
============

The morbidity and mortality of rectal cancer are high in the Western world although there is a significant improvement in diverse treatment methods and overall survival (OS) in the last decade.[@b1-ott-9-3127] The Tumor Node Metastasis (TNM) staging system and Dukes' staging system are beneficial to stratify patients into different treatment strategies, but the prognosis varies even in patients at the same stage. Prognostic significance of supplementary items to current tumor staging system has been investigated in recent years, such as inflammatory factors, proteins, and genes; nevertheless, no reliable markers have been found.[@b2-ott-9-3127] Therefore, the introduction of some reliable and affordable markers is essential for predicting prognosis for patients with rectal cancer and providing personalized therapy strategies.

The relationship between cancer and inflammation was first reported by Virchow in 1863.[@b3-ott-9-3127] In recent years, an increasing number of studies have reported the association between systematic inflammatory response and prognosis of cancer.[@b4-ott-9-3127] An elevated peripheral blood neutrophil-to-lymphocyte ratio (NLR), a serum-based inflammatory index, has been recognized as a predictor of poor prognosis in various cancers, including breast cancer, renal cell carcinoma, gastric cancer, and hepatocellular carcinoma.[@b5-ott-9-3127]--[@b8-ott-9-3127] Accumulating evidence indicated the potential relationship between elevated NLR and poorer survival in rectal cancer. But these results remain inconclusive due to the different study designs and limited number of patients across studies.[@b9-ott-9-3127],[@b10-ott-9-3127] Therefore, we systematically performed a meta-analysis based on relevant studies to explore the prognostic value of NLR on survival in patients with rectal cancer.

Materials and methods
=====================

Literature research
-------------------

PubMed and EMBASE were systematically searched up with search strategy based on the following terms: ("neutrophil lymphocyte ratio" OR "neutrophil-to-lymphocyte ratio" OR "neutrophil-lymphocyte ratio" OR NLR) AND ("rectal neoplasms" OR "rectal neoplasm\*" OR "rectal tumor\*" OR "rectal cancer\*" OR "rectum tumor\*" OR "rectum cancer\*" OR "rectum neoplasm\*"). Any restriction including language, study design, human research, and so on is not permitted. And the latest search was conducted on November 11, 2015. Besides, manual search of references in relevant reviews was performed to receive potential articles.

Inclusion and exclusion criteria
--------------------------------

Two authors independently reviewed the candidate studies, and the discrepancies were resolved by discussions. The guidance of selecting eligible studies for our meta-analysis was accorded to predefined inclusion and exclusion criteria. Inclusion criteria were 1) the diagnosis of rectal cancer confirmed by pathological examination; 2) the associations between NLR and OS, disease-free survival (DFS) or recurrence-free survival (RFS); 3) sufficient data to estimate the hazard ratio (HR) and 95% confidence interval (CI); and 4) the NLR measured before treatment. Exclusion criteria were as follows: 1) study types including case report, case series, letter, editorial, and review; 2) insufficient or unspecific data of NLR; 3) languages other than English; and 4) nonhuman researches.

Data extraction and quality assessment
--------------------------------------

Data of identified studies were extracted by two investigators independently. The latest study with complete data was included in the meta-analysis when the data overlapped cross studies. The following information was extracted: author, year of publication, country of study, sample size, age, TNM stage, treatment, cutoff value, survival analysis, duration, and follow-up time. The quality assessment of included studies was conducted by two reviewers independently using the Newcastle-Ottawa Quality Assessment Scale.[@b11-ott-9-3127] Any discrepancies were discussed and resolved in the process.

Statistical analysis
--------------------

HR and 95% CI were gained directly from included studies or estimation based on methods by Parmar et al.[@b12-ott-9-3127] We estimated pooled HRs on prognosis (OS, DFS, and RFS) to evaluate the predictive value of NLR. The significance of the pooled HRs was determined by *Z*-test, and the level of statistical significance was established as *P*\<0.05. The heterogeneity among studies was checked by the *Q*-test and Higgins *I*^2^ statistic.[@b13-ott-9-3127],[@b14-ott-9-3127] If the *P*-value for the heterogeneity test was \>0.05, the Mantel--Haenszel method-based fixed effects model was used to calculate the pooled HR.[@b15-ott-9-3127] Otherwise, the DerSimonian and Laird[@b16-ott-9-3127] method-based random effects model was used. Potential publication bias was evaluated by visual inspection of the Begg's funnel plots, and we also performed an Egger's linear regression test (*P*\<0.05 was considered a significant publication bias).[@b17-ott-9-3127] All the statistical analyses were performed using a software program, STATA Version 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Study selection and characteristics
-----------------------------------

The flowchart of the included studies is shown in [Figure 1](#f1-ott-9-3127){ref-type="fig"}. A total of 242 records were identified through database search and other sources in the initial search. According to the predefined inclusion and exclusion criteria, seven studies with 959 patients published from 2010 to 2015 were included in the meta-analysis. Main characteristics of the included studies are listed in [Table 1](#t1-ott-9-3127){ref-type="table"}. The countries of studies included Japan (n=2), the UK (n=2), People's Republic of China (n=2), and Korea (n=1). As for the quality assessment, the scores of included trials ranged from 4 to 7.

NLR and OS in rectal cancer
---------------------------

A total of six trials comprising 857 patients reported HR for OS.[@b2-ott-9-3127],[@b9-ott-9-3127],[@b10-ott-9-3127],[@b18-ott-9-3127]--[@b20-ott-9-3127] A pooled HR of 13.408 (95% CI: 4.896--36.715, [Figure 2](#f2-ott-9-3127){ref-type="fig"}) showed that a higher NLR was expected to an unfavorable OS. The results of heterogeneity test indicated that there was no significant heterogeneity (*P*=0.852, *I*^2^=0.0%, [Figure 2](#f2-ott-9-3127){ref-type="fig"}). Due to relatively minor heterogeneity, further meta-regression or subgroup analysis was not conducted.

NLR and DFS in rectal cancer
----------------------------

A total of three trials including 403 patients reported HR for DFS.[@b2-ott-9-3127],[@b10-ott-9-3127],[@b18-ott-9-3127] An elevated NLR was associated with a HR for DFS of 4.368 (95% CI: 2.329--8.190, [Figure 3](#f3-ott-9-3127){ref-type="fig"}) with low heterogeneity (*P*=0.411, *I*^2^=0.0%, [Figure 3](#f3-ott-9-3127){ref-type="fig"}).

NLR and RFS in rectal cancer
----------------------------

A total of three trials comprising 433 patients reported HR for RFS.[@b9-ott-9-3127],[@b20-ott-9-3127],[@b21-ott-9-3127] An elevated NLR was related to a HR for RFS of 3.636 (95% CI: 1.876--7.048, [Figure 4](#f4-ott-9-3127){ref-type="fig"}) with low heterogeneity (*P*=0.482, *I*^2^=0.0%, [Figure 4](#f4-ott-9-3127){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was performed by excluding one individual study each time to assess the influence of each individual study on the pooled HRs for OS. The corresponding HRs did not change considerably, suggesting that the findings of this meta-analysis are credible.

Begg's funnel plot and Egger's test were conducted to evaluate the publication bias of the included cohorts in OS. Funnel plot shape did not reveal any obvious evidence of asymmetry. The *P*-value for Egger's test in the HR for OS was 0.057 ([Figure 5](#f5-ott-9-3127){ref-type="fig"}). Overall, the above results suggested that publication bias was not evident in this meta-analysis.

Discussion
==========

Prior studies have suggested the association between high NLR and poor outcome of patients with various types of cancer. Our analysis combined the outcomes of 959 patients with rectal cancer from seven studies to evaluate the prognostic effect of NLR, demonstrating that the elevated NLR was associated with unfavorable OS (HR: 13.408), DFS (HR: 4.368), and RFS (HR: 3.636). The results of sensitivity analyses suggested that our review was reliable and stable. There was no significant publication bias in our study. To our knowledge, the present study is the first meta-analysis assessing the association between NLR and prognosis in rectal cancer.

The mechanism underlying the association between elevated NLR and poor outcome in rectal cancer remains complicated. The first potential mechanism is that inflammation contributes to the construction of "tumor microenvironment" by supplying tumor-promoting cytokines that active some signalings, such as nuclear factor kB (NF-kB), transducer and activator of transcription 3 (STAT3).[@b22-ott-9-3127],[@b23-ott-9-3127] These transcription factors possibly induce genes in premalignant cells to stimulate cell proliferation and survival, as well as angiogenesis, invasiveness, motility, chemokine, and cytokine production.[@b24-ott-9-3127] Particularly, interleukin 6 (IL-6) is an important tumor-promoting cytokine and its tumor-promoting effect is mainly exerted via STAT3.[@b25-ott-9-3127] Serum concentration of IL-6 has been reported to be increased in colorectal cancer and other 12 different cancer types and has been associated with tumor stage and adverse prognosis.[@b26-ott-9-3127] There are also other tumor-promoting cytokines such as IL-23, tumor necrosis factor-a, and IL-1b.[@b27-ott-9-3127]--[@b30-ott-9-3127] Second, lymphocytes can reduce tumor infiltration via a series of subtypes, lymphocytes, activated T-cells, and natural killer cells, which has been shown to improve the survival of patients with cancer.[@b31-ott-9-3127]--[@b33-ott-9-3127] The dysfunction of T-lymphocyte, as one common kind of tumor infiltrating lymphocyte, could result in immune escape of tumor cells.[@b34-ott-9-3127],[@b35-ott-9-3127] The lymphocyte-dependent antitumoral immune response could be inhibited by the recruitment of inflammatory cells. In addition, inflammation promotes the accumulation of myeloid-derived suppressor cells and regulatory T-cells (Tregs), both of which downregulate the immune surveillance and antitumor immunity.[@b36-ott-9-3127],[@b37-ott-9-3127] In general, elevated NLR caused by neutrophilia or lymphopenia, denotes enhanced inflammatory response and suppression of immunity. As tumorigenesis and tumor progression in humans often take decades, NLR as a predictor can be used to tailor the personalized treatment strategy.

In addition to NLR, other markers of inflammatory response, such as platelet lymphocyte ratio (PLR) and the modified Glasgow prognostic score (mGPS), have been shown to be prognostic factors for survival in colorectal cancer.[@b38-ott-9-3127],[@b39-ott-9-3127] The mGPS was based on C-reactive protein and albumin. Toiyama et al[@b40-ott-9-3127] reported that elevated C-reactive protein was an adverse prognostic factor for OS and DFS in 84 patients with locally advanced rectal cancer in 2013. Roxburgh et al[@b41-ott-9-3127] reported that mGPS is an important independent predictor of 3-year survival in colon and rectal cancers. The multivariate analysis of Powell showed that mGPS (*P*=0.028) was independently related to cancer-specific survival.[@b42-ott-9-3127] None of our included studies have reported the relationship between mGPS and survival in the multivariate analysis. However, these parameters are not routinely measured in daily clinical practice. In contrast, NLR owns the advantage of low economic cost and wide availability over the above laboratory items. NLR can be obtained from peripheral blood routine test, which is routinely exanimated before the treatment and consequently costs no extra expenditure. Changes of NLR are easily monitored during the process of treatment. PLR is available from a routine blood test such as NLR. In a study of 200 patients undergoing curative resection for rectal cancer, both NLR and PLR were shown to be prognostic biomarkers of OS.[@b43-ott-9-3127] Two of our included studies reported the information about PLR. In the study of Toiyama we included, high platelet before chemoradiation therapy is an independent predictor of poor OS and DFS in rectal cancer patients, while platelet and NLR were significantly correlated.[@b10-ott-9-3127] The study of Carruthers reported that higher PLR showed no significant association with OS, DFS, and time to local recurrence, while higher NLR was shown to be associated with all outcomes.[@b18-ott-9-3127] Based on the limited studies providing comparison between NLR and other inflammatory markers, we think that it is premature to conclude which inflammatory marker is better, and more relevant studies are needed to draw a conclusion.

However, NLR is a parameter in low specificity. An elevated NLR could be induced by many concurrent diseases and conditions, such as infections and medications. NLR also appears to be prognostic in noncancer conditions such as acute pancreatitis or cardiac events.[@b44-ott-9-3127],[@b45-ott-9-3127] Some of our included studies did not control the different concurrent conditions or report them in detail. We consider these as confounding factors for the explanation of the prognostic role of NLR.

Here are some limitations in this study. First, only summarized data rather than individual data were available for analysis. Second, the number of studies we included is small. We included one abstract with poor quality in order to get more information. Third, we only included studies reporting HR for OS, DFS, or RFS and consequently other studies focusing on the prognostic effect of NLR were excluded because of their different effect sizes or endpoints. Fourth, among the including studies, the only abstract reported unclear endpoint of multivariate HR, thus we selected the univariate HR. Because of large variations in the covariates of multivariate HR across included studies, sensitivity analyses in accordance with adjustment variables were not conducted. Both of the above may lead to bias toward overestimation of prognostic effect of NLR. Fifth, the unified cutoff value for high NLR contributes to between-studies heterogeneity. Sixth, there are some other powerful variables associated with survival of rectal cancer, such as level of serum alpha fetoprotein, tumor location, tumor stage, and depth of invasion. The correlations between NLR and the above factors remain unclear. There was no sufficient data for us to perform further subgroup analysis. Seventh, other existing inflammatory conditions were not discussed in the original studies and the control samples with inflammation from noncancer patients were lacking in the included studies.

In our opinion, with regard to research design, the strategies to bring NLR into a clinically relevant biomarker are first, the investigators could include control samples with inflammation from noncancer patients to test the specificity of NLR. Second, researchers should perform multivariate analysis to gain a HR for NLR's prognostic role and take many clinicopathological parameters into account, such as tumor stage before chemoradiation therapy, tumor size, tumor location, adjuvant chemotherapy, the prechemoradiation therapy serum carcinoembryonic antigen level, alpha fetoprotein, ypTNM staging, depth of invasion, histological type, pathological tumor response, lymph node metastasis, and so on. The multivariate HR of the specific variable removes the influences of other variables and assesses the prognostic effect of NLR as an independent factor.

Conclusion
==========

Our results indicated that elevated NLR might be a poor prognostic factor for survival in patients with rectal cancer. NLR, an inexpensive, widely available, and reproducible index, is a promising prognostic indicator for patients with rectal cancer. It could be useful in stratifying patients and determining individual therapy plans. However, these results need to be interpreted cautiously before the clinical application of NLR as an independent biomarker because of the limitations listed above. More multicenter prospective cohorts and large-scale investigations are warranted to validate the value of NLR in the prognosis of rectal cancer, thus leading to more detailed patient selection when applying it to clinical decisions.
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![Forest plots of studies evaluating HR with 95% CI of NLR for OS.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival.](ott-9-3127Fig2){#f2-ott-9-3127}

![Forest plots of studies evaluating HR with 95% CI of NLR for DFS.\
**Abbreviations:** CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio.](ott-9-3127Fig3){#f3-ott-9-3127}

![Forest plots of studies evaluating HR with 95% CI of NLR for RFS.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; RFS, recurrence-free survival.](ott-9-3127Fig4){#f4-ott-9-3127}

![Begg's funnel plot for the assessment of potential publication bias.\
**Abbreviations:** HR, hazard ratio; se, standard error.](ott-9-3127Fig5){#f5-ott-9-3127}

###### 

Characteristics of included studies

  Study                               Year   Country                      Sample size (n)   Age (years), mean (range)   TNM (I/II/III/IV)   Treatment (predominant)   Cut-off value   Survival analysis   Duration     Follow-up, mean (range)   NOS
  ----------------------------------- ------ ---------------------------- ----------------- --------------------------- ------------------- ------------------------- --------------- ------------------- ------------ ------------------------- -----
  Toiyama et al[@b10-ott-9-3127]      2015   Japan                        89                65.0 (33--80)               13/15/61/0          CRT, S                    3               OS, DFS             2001--2012   56 m (2--147 m)           7
  Liu et al[@b19-ott-9-3127]          2010   People's Republic of China   123               61.28 (28--81)              17/59/47 (III/IV)   S                         2               OS                  1999--2006   NR                        6
  Nagasaki et al[@b9-ott-9-3127]      2015   Japan                        201               61 (28--81)                 NR                  CRT, S                    3               OS, RFS             2004--2012   51.2 m (3.6--120.1 m)     8
  Carruthers et al[@b18-ott-9-3127]   2012   UK                           115               63.8 (32.3--81.1)           NR                  CRT                       5               OS, DFS             2000--2005   37.1 m                    6
  Harji et al[@b20-ott-9-3127]        2012   UK                           130               NR                          NR                  S                         4.81            OS, RFS             2005--2011   NR                        4
  Shen et al[@b2-ott-9-3127]          2014   People's Republic of China   199               55 (22--76)                 0/26/173/0          CRT/S                     2.8             OS, DFS             2006--2011   31 m (1--84 m)            7
  Kim et al[@b21-ott-9-3127]          2014   Korea                        102               NR                          NR                  CRT/S                     3               CSS, RFS            1996--2012   39 m (3--238 m)           7

**Abbreviations:** CRT, chemoradiation therapy; CSS, cancer-specific survival; DFS, disease-free survival; NOS, Newcastle-Ottawa Quality Assessment Scale; NR, not reported; OS, overall survival; RFS, recurrence-free survival; S, surgery; UK, United Kingdom; m, months.
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